Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction

Clinical Research in Cardiology

Volumn 100, Issue 12, 2011, Pages 1069-1076

  Gu, Youlan L ^a   Voors, Adriaan A ^a   Zijlstra, Felix ^b   Hillege, Hans L ^a   Struck, Joachim ^c   Masson, Serge ^d   Vago, Tarcisio ^e   Anker, Stefan D ^f   Van Den Heuvel, Ad F M ^a   Van Veldhuisen, Dirk J ^a   De Smet, Bart J G L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c THERMO FISHER SCIENTIFIC   (Germany)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute myocardial infarction; Biomarkers; Copeptin; Temporal release pattern; Troponin

Indexed keywords

BIOLOGICAL MARKER; COPEPTIN; CREATINE KINASE MB; TROPONIN T; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYMPTOM; SYSTOLIC BLOOD PRESSURE;

ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CREATINE KINASE, MB FORM; GLYCOPEPTIDES; HUMANS; MYOCARDIAL INFARCTION; NETHERLANDS; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME; TROPONIN T; UP-REGULATION;

EID: 84856003210     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-011-0343-y     Document Type: Article

References (32)

1. Thygesen K, Alpert JS, White HD et al (2007) Universal definition of myocardial infarction. Circulation 116:2634-2653. doi: 10.1161/CIRCULATIONAHA. 107.187397 (Pubitemid 350182388)
2. Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH (2007) National academy of clinical biochemistry and IFCC committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: Analytical issues for biochemical markers of acute coronary syndromes. Circulation 115:e352-e355. doi:10.1161/CIRCULATIONAHA.107.182881 (Pubitemid 46648623)
3. Morrow DA, Cannon CP, Jesse RL et al (2007) National academy of clinical biochemistry laboratory medicine practice guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 53:552-574. doi:10.1373/ clinchem.2006.084194 (Pubitemid 46580223)
4. Keller T, Post F, Tzikas S et al (2010) Improved outcome in acute coronary syndrome by establishing a chest pain unit. Clin Res Cardiol 99:149-155. doi:10.1007/s00392-009-0099-9
5. Bauer T, Hoffmann R, Jünger C et al (2009) Efficacy of a 24-h primary percutaneous coronary intervention service on outcome in patients with ST elevation myocardial infarction in clinical practice. Clin Res Cardiol 98:171-178. doi:10.1007/s00392- 008-0738-6
6. Itoi K, Jiang YQ, Iwasaki Y, Watson SJ (2004) Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus. J Neuroendocrinol 16:348-355. doi:10.1111/j.0953-8194.2004.01172.x (Pubitemid 38618652)
7. Keller T, Tzikas S, Zeller T et al (2010) Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 55:2096-2106. doi:10.1016/j.jacc.2010.01.029
8. Reichlin T, Hochholzer W, Stelzig C et al (2009) Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 54:60-68. doi:10.1016/j.jacc.2009.01.076
9. Voors AA, Belonje AM, Zijlstra F et al (2010) A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 31:2593-2600. doi:10.1093/eurheartj/ehq304
10. Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112-119. doi: 10.1373/clinchem.2005.060038 (Pubitemid 43032474)
11. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL (2006) Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 114:1572-1580. doi:10.1161/ CIRCULATIONAHA.105.610642 (Pubitemid 44547427)
12. Royston P, Altman DG (1994) Regression using fractional polynomials of continuous covariates: Parsimonious parametric modelling (with Discussion). Appl Stat 43:429-467
13. Katan M, Morgenthaler N, Widmer et al (2008) Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 29:341-346
14. Morgenthaler NG, Struck J, Jochberger S, Dunser MW (2008) Copeptin: Clinical use of a new biomarker. Trends Endocrinol Metab 19:43-49. doi:10.1016/j.tem.2007.11.001 (Pubitemid 351317895)
15. Jochberger S, Morgenthaler NG, Mayr VD et al (2006) Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 91:4381-4386. doi:10.1210/jc.2005- 2830 (Pubitemid 44833413)
16. Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M (2007) Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 28:219-226. doi:10.1097/SHK. 0b013e318033e5da (Pubitemid 47220835)
17. Muller B, Morgenthaler N, Stolz D et al (2007) Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 37:145-152. doi:10.1111/j.1365-2362. 2007.01762.x (Pubitemid 46066494)
18. Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D (2003) Circulating vasopressin levels in septic shock. Crit Care Med 31:1752-1758. doi:10.1097/01.CCM.0000063046. 82359.4A (Pubitemid 36714233)
19. Stolz D, Christ-Crain M, Morgenthaler NG et al (2007) Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 131:1058-1067. doi:10.1378/ chest.06-2336 (Pubitemid 46608707)
20. Staub D, Morgenthaler NG, Buser C et al (2009) Use of copeptin in the detection of myocardial ischemia. Clin Chim Acta 399:69-73. doi:10.1016/j.cca. 2008.09.016
21. Szinnai G, Morgenthaler NG, Berneis K et al (2007) Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 92:3973-3978. doi:10.1210/jc.2007-0232 (Pubitemid 47607649)
22. Pirzada FA, Ekong EA, Vokonas PS, Apstein CS, Hood WB Jr (1976) Experimental myocardial infarction. XIII. Sequential changes in left ventricular pressure-length relationships in the acute phase. Circulation 53:970-975
23. Khan SQ, Dhillon OS, O'Brien RJ et al (2007) C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester acute myocardial infarction peptide (LAMP) study. Circulation 115:2103-2110. doi:10.1161/ CIRCULATIONAHA.106.685503 (Pubitemid 46659061)
24. Antman EM, Anbe DT, Armstrong PW et al (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American college of cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 44:671-719. doi:10.1016/j.jacc.2004.07. 002
25. Keller T, Zeller T, Peetz D et al (2009) Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 361:868-877. doi:10.1056/NEJMoa0903515
26. Reichlin T, Hochholzer W, Bassetti S et al (2009) Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 361:858-867. doi:10.1056/NEJMoa0900428
27. Kurz K, Giannitsis E, Becker M, Hess G, Zdunek D, Katus HA (2011) Comparison of the new high sensitive cardiac troponin T with myoglobin, h-FABP and cTnT for early identification of myocardial necrosis in the acute coronary syndrome. Clin Res Cardiol 100:209-215. doi:10.1007/s00392-010-0230-y
28. Eggers KM, Oldgren J, Nordenskjold A, Lindahl B (2004) Diagnostic value of serial measurement of cardiac markers in patients with chest pain: Limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J 148:574-581. doi:10.1016/j.ahj.2004.04.030 (Pubitemid 39349374)
29. Meune C, Zuily S, Wahbi K, Claessens YE, Weber S, Chenevier- Gobeaux C (2011) Combination of copeptin and high-sensitivity cardiac troponin T assay in unstable angina and non-ST-segment elevation myocardial infarction: A pilot study. Arch Cardiovasc Dis 104:4-10. doi:10.1016/j.acvd.2010.11.002
30. Kelly D, Squire IB, Khan SQ et al (2008) C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail 14:739-745. doi:10.1016/j.cardfail.2008. 07.231
31. Voors AA, von Haehling S, Anker SD et al (2009) C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: Results from the OPTIMAAL study. Eur Heart J 30:1187-1194. doi:10.1093/eurheartj/ehp098
32. Das SR, Drazner MH, Dries DL et al (2005) Impact of body mass and body composition on circulating levels of natriuretic peptides: Results from the Dallas Heart Study. Circulation 112:2163-2168. doi:10.1161/CIRCULATIONAHA.105. 555573 (Pubitemid 41475811)